Are There Differences in Gut Microbiome in Patients with Type 2 Diabetes Treated by Metformin or Metformin and Insulin?

References

• DeFronzo RA. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med. 2010;123(3 Suppl):S38–S48. doi:10.1016/j.amjmed.2009.12.008
   PubMed Web of Science ®Google Scholar
• Defeudis G, Rossini M, Khazrai YM, et al. The gut microbiome as possible mediator of the beneficial effects of very low calorie ketogenic diet on type 2 diabetes and obesity: a narrative review. Eat Weight Disord. 2022;27(7):2339–2346. doi:10.1007/s40519-022-01434-2
   Web of Science ®Google Scholar
• Makki K, Deehan EC, Walter J, Bäckhed F. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe. 2018;23(6):705–715. doi:10.1016/j.chom.2018.05.012
   PubMed Web of Science ®Google Scholar
• Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19(1):55–71. doi:10.1038/s41579-020-0433-9
   PubMed Web of Science ®Google Scholar
• Dias A, Cordeiro G, Estevinho MM, et al. Gut bacterial microbiome composition and statin intake—A systematic review. Pharmacol Res Perspect. 2020;8:e00601. doi:10.1002/prp2.601
   PubMed Web of Science ®Google Scholar
• Sedighi M, Razavi S, Navab-Moghadam F, et al. Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals. Microb Pathog. 2017;111:362–369. doi:10.1016/j.micpath.2017.08.038
   PubMed Web of Science ®Google Scholar
• Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5(2):e9085. doi:10.1371/journal.pone.0009085
   PubMed Web of Science ®Google Scholar
• Myhrstad MCW, Tunsjø H, Charnock C, Telle-Hansen VH, Fiber D, Microbiota G. Metabolic regulation-current status in human randomized trials. Nutrients. 2020;12(3):859. doi:10.3390/nu12030859
   Web of Science ®Google Scholar
• Zhou Z, Sun B, Yu D, Zhu C. Gut microbiota: an important player in type 2 diabetes mellitus. Front Cell Infect Microbiol. 2022;12:834485. doi:10.3389/fcimb.2022.834485
   PubMed Web of Science ®Google Scholar
• Bielka W, Przezak A, Pawlik A. The role of the gut microbiota in the pathogenesis of diabetes. Int J Mol Sci. 2022;23(1):480. doi:10.3390/ijms23010480
   PubMed Web of Science ®Google Scholar
• Doestzada M, Vila AV, Zhernakova A, et al. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell. 2018;9(5):432‐445. doi:10.1007/s13238-018-0547-2
   Web of Science ®Google Scholar
• Sharma A, Buschmann MM, Gilbert JA. Pharmacomicrobiomics: the holy grail to variability in drug response? Clin Pharmacol Ther. 2019;106(2):317‐328. doi:10.1002/cpt.1437
   Web of Science ®Google Scholar
• Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, et al. Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care. 2017;40:54–62. doi:10.2337/dc16-1324
   Web of Science ®Google Scholar
• Wang H, Tang W, Zhang P, et al. Modulation of gut microbiota contributes to effects of intensive insulin therapy on intestinal morphological alteration in high-fat-diet-treated mice. Acta Diabetol. 2020;57(4):455–467. doi:10.1007/s00592-019-01436-0
   Web of Science ®Google Scholar
• Lee SH, Yun Y, Kim SJ, et al. Association between cigarette smoking status and composition of gut microbiota: population based cross-sectional study. J Clin Med. 2018;7(9):282–286. doi:10.3390/jcm7090282
   Web of Science ®Google Scholar
• Klindworth A, Preusse E, Schweer T, et al. Evaluation of general 16S ribosomal RNA gene PCR primes for classical and next-generation sequencing-based on diversity studies. Nucleid Acid Res. 2013;41(1):21–29. doi:10.1093/nar/gks808
   Web of Science ®Google Scholar
• Clooney AG, Fouhy F, Sleator RD, et al. Comparing apples and oranges?: next generation sequencing and its impact on microbiome analysis. PLoS One. 2016;11(2):e0148028. doi:10.1371/journal.pone.0148028
   PubMed Web of Science ®Google Scholar
• Lv Y, Zhao X, Guo W, et al. The relationship between frequently used glucose-lowering agents and gut microbiota in type 2 diabetes mellitus. J Diabetes Res. 2018;2018:1890978. doi:10.1155/2018/1890978
   Web of Science ®Google Scholar
• Cao TTB, Wu KC, Hsu JL, et al. Effects of Non-insulin anti-hyperglycemic agents on gut microbiota: a systematic review on human and animal studies. Front Endocrinol. 2020;11:573891. doi:10.3389/fendo.2020.573891
   Web of Science ®Google Scholar
• Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15(10):569–589. doi:10.1038/s41574-019-0242-2
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Hiel S, Delzenne NM. Metformin: old friend, new ways of action-implication of the gut microbiome? Curr Opin Clin Nutr Metab Care. 2018;21:294–301. doi:10.1097/MCO.0000000000000468
   Web of Science ®Google Scholar
• Deng J, Zeng L, Lai X, et al. Metformin protects against intestinal barrier dysfunction via AMPKα1-dependent inhibition of JNK signalling activation. J Cell Mol Med. 2018;22(1):546–557. doi:10.1111/jcmm.13342
   PubMed Web of Science ®Google Scholar
• McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426–435. doi:10.1007/s00125-015-3844-9
   PubMed Web of Science ®Google Scholar
• Chávez-Carbajal A, Pizano-Zárate ML, Hernández-Quiroz F, et al. Characterization of the gut microbiota of individuals at different T2D stages reveals a complex relationship with the host. Microorganisms. 2020;8(1):94. doi:10.3390/microorganisms8010094
   PubMed Web of Science ®Google Scholar
• Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:102590. doi:10.1016/j.ebiom.2019.11.051
   PubMed Web of Science ®Google Scholar
• Cosola C, Rocchetti MT, Sabatino A, Fiaccadori E, Di Iorio BR, Gesualdo L. Microbiota issue in CKD: how promising are gut-targeted approaches? J Nephrol. 2019;32(1):27–37. doi:10.1007/s40620-018-0516-0
   PubMed Web of Science ®Google Scholar
• Cai K, Ma Y, Cai F, et al. Changes of gut microbiota in diabetic nephropathy and its effect on the progression of kidney injury. Endocrine. 2022;76(2):294–303. doi:10.1007/s12020-022-03002-1
   PubMed Web of Science ®Google Scholar
• Salonen A, Lahti L, Salojärvi J, et al. Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men. ISME J. 2014;8:2218. doi:10.1038/ismej.2014.63
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl. 1):S125–S143. doi:10.2337/dc22-S00
   PubMedGoogle Scholar
• Ampudia-Blasco FJ, Palanca A, Trillo JL, Navarro J, Real JT. Therapeutic inertia in patients with type 2 diabetes treated with non-insulin agents. J Diabetes Complications. 2021;35(3):107828. doi:10.1016/j.jdiacomp.2020.107828
   Web of Science ®Google Scholar
• Rattelman CR, Ciemins EL, Stempniewicz N, Mocarski M, Ganguly R, Cuddeback JK. A retrospective analysis of therapeutic inertia in type 2 diabetes management across a diverse population of health care organizations in the USA. Diabetes Ther. 2021;12(2):581–594. doi:10.1007/s13300-020-00993-w
   Web of Science ®Google Scholar